Cannell & Spears LLC Reduces Position in Novo Nordisk A/S $NVO

Key Points

• Cannell & Spears LLC reduced its Novo Nordisk stake by 69.4% in Q3, selling 27,102 shares and retaining 11,947 shares worth about $663,000.
• The FDA issued a warning over unreported semaglutide adverse events and an investor class‑action/investigation has been launched, heightening regulatory and legal risk for the company.
• Analyst sentiment has cooled toward "Hold" (MarketBeat consensus target $49.93) and several downgrades, negative press and a stock slump have weighed on the shares.

Cannell & Spears LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 69.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,947 shares of the company's stock after selling 27,102 shares during the period. Cannell & Spears LLC's holdings in Novo Nordisk A/S were worth $663,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of NVO. True Wealth Design LLC grew its holdings in Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company's stock valued at $25,000 after purchasing an additional 300 shares during the period. Guerra Advisors Inc bought a new position in shares of Novo Nordisk A/S in the third quarter worth about $25,000. Strengthening Families & Communities LLC bought a new position in shares of Novo Nordisk A/S in the third quarter worth about $30,000. Allianz SE lifted its position in shares of Novo Nordisk A/S by 70.0% during the 3rd quarter. Allianz SE now owns 578 shares of the company's stock valued at $32,000 after buying an additional 238 shares in the last quarter. Finally, Financial Life Planners bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $33,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

Analysts Set New Price Targets

Several equities research analysts recently issued reports on NVO shares. Jefferies Financial Group raised shares of Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a report on Thursday, February 12th. Zacks Research upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 10th. Kepler Capital Markets cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Tuesday, February 24th. The Goldman Sachs Group restated a "neutral" rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Finally, CICC Research began coverage on shares of Novo Nordisk A/S in a research note on Friday, January 9th. They set an "outperform" rating and a $73.50 target price on the stock. Four analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and a consensus target price of $49.93.

Novo Nordisk A/S Stock Down 0.1%

NYSE NVO opened at $37.99 on Monday. Novo Nordisk A/S has a 12 month low of $35.85 and a 12 month high of $82.57. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The stock has a market cap of $169.61 billion, a PE ratio of 10.95 and a beta of 0.74. The stock's 50 day moving average is $50.14 and its 200 day moving average is $51.73.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 23.63%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.